Results 131 to 140 of about 112,075 (306)

Harnessing Algal Biorefineries for Waste to Wealth Paradigm: A Pathway Toward Circular and Sustainable Bioeconomy

CleanMat, EarlyView.
This review highlights the use of wastewater from various sources including industrial, municipal, and agricultural effluents for microalgal cultivation. It emphasizes on the integrated approach of wastewater treatment and microalgal biomass production for high value‐added bioproducts such as biofuels, animal feed, biofertilizers, bioplastics while ...
Prachi Bhatnagar, Sonia Choudhary, Anwesha Dey, Krishna Mohan Poluri   +3 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Bexicaserin in Healthy Participants: A First‐in‐Human Randomized, Double‐Blind, Placebo‐Controlled Single Ascending Dose Escalation Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective 5‐hydroxytryptamine 2C (5‐HT2C) superagonist in development for the treatment of seizures in developmental and epileptic encephalopathies (DEEs). This double‐blind, placebo‐controlled, single ascending dose (SAD) Phase 1 study aimed to assess the safety, tolerability, and pharmacokinetic (PK) and ...
Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R Srinivas, Randall Kaye   +6 more
wiley   +1 more source

Paediatric non-alcoholic fatty liver disease: impact on patients and mothers' quality of life [PDF]

, 2013
Background: Non-alcoholic fatty liver disease (NAFLD) is one of the causes of fatty liver in adults and is currently the primary form of chronic liver disease in children and adolescents. However, the psychological outcome (i.e.
Armando, M, Bedogni, G, De Peppo, L, Della Corte, C, Fatta, L, Fatta, LAURA MARIA, Lofino, G, Mazzone, L, Nobili, V., Postorino, V, Vassena, L, Vicari, S   +11 more
core   +2 more sources

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Effects of High‐ and Low‐Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open‐label, two‐period, crossover food effect study that evaluated the effect of high‐ and low‐fat meals on 20 mg votoplam in healthy participants. There was a washout of
Lucy Lee, Amy‐Lee Richards, Nageswara Reddy, Brian Beers, Lee Golden, Ronald Kong   +5 more
wiley   +1 more source

Beneficial role of bioactive lipids in the pathobiology, prevention, and management of HBV, HCV and alcoholic hepatitis, NAFLD, and liver cirrhosis: A review

Journal of Advanced Research, 2019
It has been suggested that hepatitis B virus (HBV)- and hepatitis C virus (HCV)-induced hepatic damage and cirrhosis and associated hypoalbuminemia, non-alcoholic fatty liver disease (NAFLD), and alcoholic fatty liver disease (AFLD) are due to an ...
Undurti N. Das
doaj   +1 more source

Incidence of major cardiovascular events in patients with metabolic dysfunction‐associated steatotic liver disease in the general population

European Journal of Heart Failure, EarlyView.
Aims Major adverse cardiovascular events (MACE) related to cardiovascular disease are a major cause of death in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD). We explored the impact of MASLD on incident MACE and overall mortality in the general population in Germany.
Yvonne Huber, Lea Hofmann, Jürgen H. Prochaska, Thomas Koeck, Julian Chalabi, Norbert Pfeiffer, Manfred Beutel, Konstantin Strauch, Karl J. Lackner, Oliver Tüscher, Thomas Münzel, Matthias M. Weber, Julia Weinmann‐Menke, Philipp Wild, Peter R. Galle, Jörn M. Schattenberg   +15 more
wiley   +1 more source

Changing perspectives on liver transplantation in 1988. [PDF]

, 1988
After liver transplantation for cancer, there is a high incidence of disease recurrence within 18 to 36 months for most tumors, although there are a small number of long-term survivors.
Gordon, RD, Starzl, TE
core  

A Comprehensive Review of Probiotics in Alleviating Hyperuricemia: Mechanisms, Strain Engineering, and Food Applications

Food Bioengineering, EarlyView.
Screening and modification of probiotics that can efficiently reduce uric acid provide a new strategy for food‐grade hyperuricemia intervention. ABSTRACT Hyperuricemia has become one of the most prevalent global epidemics, significantly impacting both the economy and the health of individuals.
Le Wang, Qi Wu, Mengjia Zhang, Zifu Ni, Pengshuai Zhang, Siyuan Bai, Yibin Wang, Zhongke Sun   +7 more
wiley   +1 more source

Current management of alcoholic liver disease

Фундаментальная и клиническая медицина, 2019
In Russia, liver diseases largely contribute to the mortality. Here we review the literature on current management of alcoholic liver disease, which remains the leading cause of cirrhosis worldwide.
V. V. Tsukanov, A. V. Vasyutin, Y. L. Tonkikh   +2 more
doaj   +1 more source